Obesity and cancer: The role of adipose tissue and adipo-cytokines-induced chronic inflammation

Journal of Cancer

Volumn 7, Issue 15, 2016, Pages 2346-2359

  Divella, Rosa ^a   De Luca, Raffaele ^a   Abbate, Ines ^a   Naglieri, Emanuele ^a   Daniele, Antonella ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Adipocytes inflammation; Adipocytokine; Cancer; Obesity

Indexed keywords

ADIPOCYTOKINE; INTERLEUKIN 1; INTERLEUKIN 6; LEPTIN; TUMOR NECROSIS FACTOR;

ADIPOSE TISSUE; CANCER RISK; CHRONIC INFLAMMATION; CLINICAL OUTCOME; HUMAN; HYPERPLASIA; HYPERTROPHY; HYPOXIA; INSULIN RESISTANCE; ISCHEMIA; NEOPLASM; NONHUMAN; OBESITY; OXIDATIVE STRESS; REVIEW; STROMA CELL; TUMOR GROWTH; WHITE ADIPOCYTE;

EID: 85008154360     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.16884     Document Type: Review

References (220)

1. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med 2007; 356: 213-215.
2. Kent BD, McNicholas WT, Ryan S. Insulin resistance, glucose intolerance and diabetes mellitus in obstructive sleep apnoea. J Thorac Dis 2015; 7(8): 1343-1357.
3. Owen CG, Kapetanakis VV, Rudnicka AR, et al. Body mass index in early and middle adult life: prospective associations with myocardial infarction, stroke and diabetes over a 30-year period: the British Regional Heart Study. BMJ Open 2015; 5(9): e008105. doi: 10.1136/bmjopen-2015-008105.
4. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomark Prev 2009; 18: 2569-2578.
5. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307: 491-497.
6. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638.
7. Yoon HH, Lewis MA, Shi Q, et al. Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. J Clin Oncol 2011; 29: 4561-4567.
8. Widschwendter P, Friedl TW, Schwentner L, et al. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Res 2015; 17: 129.
9. Cantarutti A, Bonn SE, Adami HO, et al. Body mass index and mortality in men with prostate cancer. Prostate 2015; 75(11): 1129-1136.
10. Fletcher I. Defining an epidemic: the body mass index in British and US obesity research 1960-2000. Sociol Health Illn 2014; 36(3): 338-353.
11. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89(6): 2548-2556.
12. Fischer-Posovszky P, Wabitsch M, Hochberg Z. Endocrinology of adipose tissue -an update. Horm Metab Res 2007; 39(5): 314-321.
13. Poulos SP, Hausman DB, Hausman GJ. The development and endocrine functions of adipose tissue. Mol Cell Endocrinol 2010; 323(1): 20-34.
14. Zhang Y, Bellows CF, Kolonin MG. Adipose tissue-derived progenitor cells and cancer. World J Stem Cells 2010; 2(5): 103-113.
15. Cristancho AG, Lazar MA. Forming functional fat: a growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol 2011; 12(11): 722-734.
16. Proença AR, Sertié RA, Oliveira AC, et al. New concepts in white adipose tissue physiology. Braz J Med Biol Res 2014; 47(3): 192-205.
17. Vázquez-Vela ME, Torres N, Tovar AR. White adipose tissue as endocrine organ and its role in obesity. Arch Med Res 2008; 39(8): 715-728.
18. Esteve Ràfols M. Adipose tissue: cell heterogeneity and functional diversity. Endocrinol Nutr 2014; 61(2): 100-112.
19. Ali AT, Hochfeld WE, Myburgh R, Pepper MS. Adipocyte and adipogenesis. Eur Cell Biol 2013; 92(6-7): 229-236.
20. Simmonds M, Burch J, Llewellyn A, et al. The use of measures of obesity in childhood for predicting obesity and the development of obesity-related diseases in adulthood: a systematic review and meta-analysis. Health Technol Assess 2015; 19(43): 1-336.
21. Laforest S, Labrecque J, Michaud A, et al. Adipocyte size as a determinant of metabolic disease and adipose tissue dysfunction. Crit Rev Clin Lab Sci 2015; 18: 1-13.
22. Stupin JH, Arabin B. Overweight and Obesity before, during and after Pregnancy: Part 1: Pathophysiology, Molecular Biology and Epigenetic Consequences. Geburtshilfe Frauenheilkd 2014; 74(7): 639-645.
23. Bays H. Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction. Curr Opin Endocrinol Diabetes Obes 2014; 21(5): 345-351.
24. Parlee SD, Lentz SI, Mori H, MacDougald OA. Quantifying size and number of adipocytes in adipose tissue. Methods Enzymol 2014; 537: 93-122.
25. Rosenow A, Noben JP, Bouwman FG, et al. Hypoxia-mimetic effects in the secretome of human preadipocytes and adipocytes. Biochim Biophys Acta 2013; 1834(12): 2761-2771.
26. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 367-377.
27. Hursting SD, Digiovanni J, Dannenberg AJ, et al. Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev Res 2012; 5: 1260-1272.
28. Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta 2013; 1831(10): 1533-1541.
29. Almendros I, Gileles-Hillel A, Khalyfa A, et al. Adipose tissue macrophage polarization by intermittent hypoxia in a mouse model of OSA: effect of tumor microenvironment. Cancer Lett 2015; 361(2):233-239.
30. Jiang C, Kim JH, Li F, et al. Hypoxia-inducible factor 1a regulates a SOCS3-STAT3-adiponectin signal transduction pathway in adipocytes. J Biol Chem 2013; 288(6): 3844-3857.
31. Petrangeli E, Coroniti G, Brini AT, et al. Hypoxia Promotes the Inflammatory Response and Stemness Features in Visceral Fat Stem Cells from Obese Subjects. J Cell Physiol 2016; 231(3): 668-679.
32. Bays H. Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction. Curr Opin Endocrinol Diabetes Obes 2014; 21(5): 345-351.
33. Lee YS, Kim JW, Osborne O, et al. Increased adipocyte O2 consumption triggers HIF-1a, causing inflammation and insulin resistance in obesity. Cell 2014; 157(6): 1339-1352.
34. Trayhurn P. Hypoxia and adipocyte physiology: implications for adipose tissue dysfunction in obesity. Annu Rev Nutr 2014; 34: 207-236.
35. Pérez-Hernández AI, Catalán V, Gómez-Ambrosi J, et al. Mechanisms linking excess adiposity and carcinogenesis promotion. Front Endocrinol (Lausanne) 2014; 5: 65.
36. Diedrich J, Gusky HC, Podgorski I. Adipose tissue dysfunction and its effects on tumor metabolism. Horm Mol Biol Clin Investig 2015; 21(1): 17-41.
37. Matafome P, Santos-Silva D, Sena CM, Seiça R. Common mechanisms of dysfunctional adipose tissue and obesity-related cancers. Diabetes Metab Res Rev 2013; 29(4): 285-295.
38. Yamada S, Utsunomiya T, Morine Y, et al. Expressions of hypoxia-inducible factor-1 and epithelial cell adhesion molecule are linked with aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy. Ann Surg Oncol 2014; 21 Suppl 3: S436-442
39. Tsai YP, Wu KJ. Hypoxia-regulated target genes implicated in tumor metastasis. J Biomed Sci 2012; 19: 102.
40. Kizaka-Kondoh S, Kuchimaru T, Kadonosono T. Pathophysiological response to hypoxia -from the molecular mechanisms of malady to drug discovery: hypoxia-inducible factor-1 (HIF-1)-active cells as a target for cancer therapy. J Pharmacol Sci 2011; 115(4): 440-445.
41. Nagasawa H. Pathophysiological response to hypoxia -from the molecular mechanisms of malady to drug discovery: drug discovery for targeting the tumor microenvironment. J Pharmacol Sci 2011; 115(4): 446-452
42. Wensveen FM, Valentic S, Šestan M, et al. The "Big Bang" in obese fat: Events initiating obesity-induced adipose tissue inflammation. Eur J Immunol 2015; 45(9): 2446-2456.
43. Huh JY, Park YJ, Ham M, Kim JB. Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity. Mol Cells 2014; 37(5): 365-371.
44. de Heredia FP, Gómez-Martínez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc 2012; 71(2): 332-338.
45. Balistreri CR, Caruso C, Candore G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm 2010; 2010:802078. doi: 10.1155/2010/802078.
46. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11(2): 85-97.
47. Hebbard L, Ranscht B. Multifaceted roles of adiponectin in cancer. Best Pract Res Clin Endocrinol Metab 2014; 28(1): 59-69.
48. Panis C, Herrera AC, Aranome AM, et al. Clinical insights from adiponectin analysis in breast cancer patients reveal its anti-inflammatory properties in non-obese women. Mol Cell Endocrinol 2014; 382(1): 190-196.
49. Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003; 285: E527-E533.
50. Smitka K, Marešová D. Adipose Tissue as an Endocrine Organ: An Update on Pro-inflammatory and Anti-inflammatory Microenvironment. Prague Med Rep 2015; 116(2): 87-111.
51. Hursting SD, Dunlap SM. Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue. Ann NY Acad Sci 2012; 1271: 82-87.
52. Lafontan M. Adipose tissue and adipocyte dysregulation. Diabetes Metab 2014, 40(1): 16-28.
53. Wood IS, de Heredia FP, Wang B, Trayhurn P. Cellular hypoxia and adipose tissue dysfunction in obesity. Proc Nutr Soc 2009; 68(4): 370-377.
54. de Ferranti S, Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem 2008; 54(6): 945-955.
55. Sommer G, Kralisch S, Stangl V, et al. Secretory products from human adipocytes stimulate proinflammatory cytokine secretion from human endothelial cells. J Cell Biochem 2009; 106(4): 729-737.
56. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005; 25(10): 2062-2068.
57. Fasshauer M, Blüher M. Adipokines in health and disease. Trends Pharmacol Sci 2015; 36(7): 461-470.
58. Blüher M. Clinical relevance of adipokines. Diabetes Metab J 2012; 36(5): 317-327
59. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin--the classical, resistin--the controversical, adiponectin--the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005; 19(4): 525-546.
60. Apostolopoulos V, de Courten MP, Stojanovska L, et al. The complex immunological and inflammatory network of adipose tissue in obesity. Mol Nutr Food Res 2015; doi: 10.1002/mnfr.201500272
61. Hutcheson J. Adipokines influence the inflammatory balance in autoimmunity. Cytokine 2015; 75(2): 272-279.
62. Walker GE, Marzullo P, Ricotti R, et al. The pathophysiology of abdominal adipose tissue depots in health and disease. Horm Mol Biol Clin Investig 2014; 19(1): 57-74.
63. Badoud F, Perreault M, Zulyniak MA, Mutch DM. Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals. FASEB J 2015; 29(3): 748-758.
64. Ghigliotti G, Barisione C, Garibaldi S, et al. Adipose tissue immune response: novel triggers and consequences for chronic inflammatory conditions. Inflammation 2014; 37(4): 1337-1353.
65. Proença AR, Sertié RA, Oliveira AC, et al. New concepts in white adipose tissue physiology. Braz J Med Biol Res 2014; 47(3): 192-205.
66. Singh P, Sharma P, Sahakyan KR, et al. Differential effects of leptin on adiponectin expression with weight gain versus obesity. Int J Obes (Lond) 2015; doi: 10.1038/ijo.2015.181.
67. Sun Y, Xun K, Wang C, et al. Adiponectin, an unlocking adipocytokine. Cardiovasc Ther 2009; 27(1): 59-75.
68. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116(7): 1784-1792.
69. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012; 55(9): 2319-2326.
70. Nigro E, Scudiero O, Monaco ML, et al. New insight into adiponectin role in obesity and obesity-related diseases. Biomed Res Int 2014; 2014:658913.
71. Riestra P, Gebreab SY, Xu R, et al. Gender-specific associations between ADIPOQ gene polymorphisms and adiponectin levels and obesity in the Jackson Heart Study cohort. BMC Med Genet 2015; 16(1): 65. doi: 10.1186/s12881-015-0214-x
72. Lai H, Lin N, Xing Z, Weng H, Zhang H. Association between the level of circulating adiponectin and prediabetes: A meta-analysis. J Diabetes Investig 2015; 6(4): 416-429.
73. Mather KJ, Goldberg RB. Clinical use of adiponectin as a marker of metabolic dysregulation. Best Pract Res Clin Endocrinol Metab 2014; 28(1): 107-117.
74. Kishida K, Funahashi T, Shimomura I. Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab 2014; 28(1): 119-130.
75. Magkos F, Fabbrini E, Patterson BW, Eagon JC, Klein S. Portal vein and systemic adiponectin concentrations are closely linked with hepatic glucose and lipoprotein kinetics in extremely obese subjects. Metabolism 2011; 60(11): 1641-1648.
76. Thompson HJ, Sedlacek SM, Wolfe P, et al. Impact of Weight Loss on Plasma Leptin and Adiponectin in Overweight-to-Obese Post Menopausal Breast Cancer Survivors. Nutrients 2015; 7(7): 5156-5176.
77. Beg MS, Saleem S, Turer A, et al. A Prospective Analysis of Plasma Adiponectin and Risk of Incident Cancer: The Dallas Heart Study. J Natl Compr Canc Netw 2015; 13(7):873-878.
78. Mauro L, Naimo GD, Ricchio E, et al. Cross-Talk between Adiponectin and IGF-IR in Breast Cancer. Front Oncol 2015; 5: 157.
79. Khan S, Shukla S, Sinha S, Meeran SM. Role of adipokines and cytokines in obesity-associated breast cancer: therapeutic targets. Cytokine Growth Factor Rev 2013; 24(6): 503-513.
80. Nigro E, Scudiero O, Sarnataro D, et al. Adiponectin affects lung epithelial A549 cell viability counteracting TNFa and IL-1ß toxicity through AdipoR1. Int J Biochem Cell Biol 2013; 45(6): 1145-1153.
81. Nakayama S, Miyoshi Y, Ishihara H, Noguchi S. Growth-inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phase entry without inducing apoptosis. Breast Cancer Res Treat 2008; 112(3): 405-410.
82. Körner A, Pazaitou-Panayiotou K, Kelesidis T, et al. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 2007; 92(3): 1041-1048.
83. Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 2006; 340(4): 1158-1166.
84. Chang CY, Chen MJ, Yang WS, et al. Hypoadiponectinemia: a useful marker of dyslipidemia in women with polycystic ovary syndrome. Taiwan J Obstet Gynecol 2012; 51(4): 583-590.
85. Guo XH, Wang JY, Gao Y, et al. Decreased adiponectin level is associated with aggressive phenotype of tongue squamous cell carcinoma. Cancer Sci 2013; 104(2): 206-213.
86. Kamada Y, Matsumoto H, Tamura S, et al. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 2007; 47(4): 556-564.
87. Lu JP, Hou ZF, Duivenvoorden WC, et al. Adiponectin inhibits oxidative stress in human prostate carcinoma cells. Prostate Cancer Prostatic Dis 2012; 15(1): 28-35.
88. Dubois V, Delort L, Billard H, et al. Breast cancer and obesity: in vitro interferences between adipokines and proangiogenic features and/or antitumor therapies? PLoS One 2013; 8(3): e58541.
89. Hillon P, Guiu B, Vincent J, Petit JM. Obesity, type 2 diabetes and risk of digestive cancer. Gastroenterol Clin Biol 2010; 34(10): 529-533.
90. Panis C, Herrera AC, Aranome AM, et al. Clinical insights from adiponectin analysis in breast cancer patients reveal its anti-inflammatory properties in non-obese women. Mol Cell Endocrinol 2014; 382(1): 190-196.
91. Medina EA, Oberheu K, Polusani SR, et al. PKA/AMPK signaling in relation to adiponectin's antiproliferative effect on multiple myeloma cells. Leukemia 2014; 28(10): 2080-2089.
92. Hebbard L, Ranscht B. Multifaceted roles of adiponectin in cancer. Best Pract Res Clin Endocrinol Metab 2014; 28(1): 59-69.
93. He Y, Lu L, Wei X, et al. The multimerization and secretion of adiponectin are regulated by TNF-alpha. Endocrine 2015; DOI 10.1007/s12020-015-0741-4, pp 1-13.
94. Nagaraju GP, Aliya S, Alese OB. Role of adiponectin in obesity related gastrointestinal carcinogenesis. Cytokine Growth Factor Rev 2015; 26(1): 83-93.
95. Slomian G, Swietochowska E, Malinowska-Borowska J, et al. Association between chemotherapy and plasma adipokines in patients with colorectal cancer. Pharmacol Rep 2014; 66(5): 902-907.
96. Gulcelik MA, Colakoglu K, Dincer H, et al. Associations between adiponectin and two different cancers: breast and colon. Asian Pac J Cancer Prev 2012; 13(1): 395-398.
97. Otokozawa S, Tanaka R, Akasaka H, et al. Associations of Serum Isoflavone, Adiponectin and Insulin Levels with Risk for Epithelial Ovarian Cancer: Results of a Case-control Study. Asian Pac J Cancer Prev 2015; 16(12): 4987-4991.
98. Zhang L, Wen K, Han X, et al. Adiponectin mediates antiproliferative and apoptotic responses in endometrial carcinoma by the AdipoRs/AMPK pathway. Gynecol Oncol 2015; 137(2): 311-320.
99. Long E, Beales IL. The role of obesity in oesophageal cancer development. Therap Adv Gastroenterol 2014; 7(6): 247-268.
100. Abe Vicente M, Donizetti Silva T, Barão K, et al. The influence of nutritional status and disease on adiponectin and TNF-a levels in colorectal cancer patients. Nutr Hosp 2014; 30(1): 140-146.
101. Huang B, Cheng X, Wang D, et al. Adiponectin promotes pancreatic cancer progression by inhibiting apoptosis via the activation of AMPK/Sirt1/PGC-1a signaling. Oncotarget 2014; 5(13): 4732-4745.
102. Nalabolu MR, Palasamudram K, Jamil K. Adiponectin and leptin molecular actions and clinical significance in breast cancer. Int J Hematol Oncol Stem Cell Res 2014; 8(1): 31-40.
103. Surmacz E. Leptin and adiponectin: emerging therapeutic targets in breast cancer. J Mammary Gland Biol Neoplasia 2013; 18(3-4): 321-332.
104. Friedman JM,Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-770.
105. Münzberg H, Morrison CD. Structure, production and signaling of leptin. Metabolism 2015; 64(1): 13-23.
106. Farooqi IS, O'Rahilly S. 20 years of leptin: human disorders of leptin action. J Endocrinol 2014; 223(1): T63-70.
107. Allison MB, Myers MG Jr. 20 years of leptin: connecting leptin signaling to biological function. J Endocrinol 2014; 223(1): T25-35.
108. Crujeiras AB, Carreira MC, Cabia B, et al. Leptin resistance in obesity: An epigenetic landscape. Life Sci 2015; pii: S0024-3205(15)00259-3.
109. Sáinz N, Barrenetxe J, Moreno-Aliaga MJ, Martínez JA. Leptin resistance and diet-induced obesity: central and peripheral actions of leptin. Metabolism 2015; 64(1): 35-46.
110. Tilg H, Moschen AR. Mechanisms behind the link between obesity and gastrointestinal cancers. Best Pract Res Clin Gastroenterol 2014; 28(4): 599-610.
111. Andò S, Barone I, Giordano C, et al. The Multifaceted Mechanism of Leptin Signaling within Tumor Microenvironment in Driving Breast Cancer Growth and Progression. Front Oncol 2014; 4:340.
112. Delort L, Rossary A, Farges MC, et al. Leptin, adipocytes and breast cancer: Focus on inflammation and anti-tumor immunity. Life Sci 2015; pii: S0024-3205(15)00232-5.
113. Grossmann ME, Mizuno NK, Bonorden MJ, et al. Role of the adiponectin leptin ratio in prostate cancer. Oncol Res 2009; 18: 269-277.
114. Lang K, Ratke J. Leptin and Adiponectin: new players in the field of tumor cell and leukocyte migration. Cell Commun Signal 2009; 7: 27.
115. Nalabolu MR, Palasamudram K, Jamil K. Adiponectin and leptin molecular actions and clinical significance in breast cancer. Int J Hematol Oncol Stem Cell Res 2014; 8(1): 31-40.
116. Sharma D, Saxena NK, Vertino PM, Anania FA. Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. Endocr Relat Cancer 2006; 13: 629-640.
117. Choi JH, Park SH, Leung PC, Choi KC. Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. J Clin Endocrinol Metab 2005; 90: 207-210.
118. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010; 72: 219-246.
119. Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Investig 2015; 21(1): 57-74.
120. Riondino S, Roselli M, Palmirotta R, et al. Obesity and colorectal cancer: role of adipokines in tumor initiation and progression. World J Gastroenterol 2014; 20(18): 5177-5190.
121. Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res 2013; 19(22): 6074-6083.
122. Pucino V, De Rosa V, Procaccini C, Matarese G. Regulatory T cells, leptin and angiogenesis. Chem Immunol Allergy 2014; 99: 155-169.
123. Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and cancer: local and systemic mechanisms. Annu Rev Med 2015; 66: 297-309.
124. Lashinger LM, Ford NA, Hursting SD. Interacting inflammatory and growth factor signals underlie the obesity-cancer link. J Nutr 2014; 144(2): 109-113.
125. Rutkowski JM, Davis KE, Scherer PE. Mechanisms of obesity and related pathologies: the macro-and microcirculation of adipose tissue. FEBS J 2009; 276(20): 5738-5746.
126. Matafome P, Santos-Silva D, Sena CM, Seiça R. Common mechanisms of dysfunctional adipose tissue and obesity-related cancers. Diabetes Metab Res Rev 2013; 29(4):285-295.
127. Apostolopoulos V, de Courten MP, Stojanovska L, et al. The complex immunological and inflammatory network of adipose tissue in obesity. Mol Nutr Food Res 2015; doi: 10.1002/mnfr.201500272.
128. Wensveen FM, Valentic S, Šestan M, et al. The "Big Bang" in obese fat: Events initiating obesity-induced adipose tissue inflammation. Eur J Immunol 2015; 45(9): 2446-2456. doi: 10.1002/eji.201545502.
129. Lee BC, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta 2014; 1842(3): 446-462.
130. Huh JY, Park YJ, Ham M, Kim JB. Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity. Mol Cells 2014; 37(5): 365-371.
131. Seijkens T, Kusters P, Chatzigeorgiou A, et al. Immune cell crosstalk in obesity: a key role for costimulation? Diabetes 2014; 63(12): 3982-3991.
132. Park J, Morley TS, Kim M, et al. Obesity and cancer-mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol 2014; 10(8): 455-465.
133. Rogers CJ, Prabhu KS, Vijay-Kumar M. The microbiome and obesity-an established risk for certain types of cancer. Cancer J 2014; 20(3): 176-180.
134. Lashinger LM, Ford NA, Hursting SD. Interacting inflammatory and growth factor signals underlie the obesity-cancer link. J Nutr 2014; 144(2): 109-113.
135. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes 2013; 2013:291546.
136. Heidland A, Klassen A, Rutkowski P, Bahner U. The contribution of Rudolf Virchow to the concept of inflammation: what is still of importance? J Nephrol 2006; 19 Suppl 10:S102-S109.
137. Schmidt A, Weber OF. In memoriam of Rudolf Virchow: a historical retrospective including aspects of inflammation, infection and neoplasia. Contrib Microbiol 2006; 13: 1-15.
138. McDonald LT, Russell DL, Kelly RR, et al. Hematopoietic stem cell-derived cancer-associated fibroblasts are novel contributors to the pro-tumorigenic microenvironment. Neoplasia 2015; 17(5):434-48.
139. Vona-Davis L, Gibson LF. Adipocytes as a critical component of the tumor microenvironment. Leuk Res 2013; 37(5): 483-484.
140. Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001 Aug; 60(3): 349-56.
141. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 2006; 74: 443-477.
142. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92(3): 347-55.
143. Trayhurn P, Wang B, Wood IS. Hypoxia and the endocrine and signalling role of white adipose tissue. Arch Physiol Biochem 2008; 114(4): 267-276.
144. Tzanavari T, Giannogonas P, Karalis KP. TNF-a and obesity. Current Directions in Autoimmunity 2010; 11: 145-156.
145. Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacologica Sinica 2008; 29(11): 1275-1288.
146. Ungefroren H, Gieseler F, Fliedner S, Lehnert H. Obesity and cancer. Horm Mol Biol Clin Investig 2015; 21(1): 5-15.
147. Jain SS, Bird RP. Elevated expression of tumor necrosis factor-alpha signaling molecules in colonic tumors of Zucker obese (fa/fa) rats. Int J Cancer 2010; 127: 2042-2050.
148. Chen YL, Yan MY, Chien SY, et al. Sann-Joong-Kuey-Jian-Tang inhibits hepatocellular carcinoma Hep-G2 cell proliferation by increasing TNF-a, Caspase-8, Caspase-3 and Bax but by decreasing TCTP and Mcl-1 expression in vitro. Mol Med Rep 2013; 7(5): 1487-1493.
149. Lukasiak S, Schiller C, Oehlschlaeger P, et al. Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene 2008; 27(46): 6068-6074.
150. Schwartz B, Yehuda-Shnaidman E. Putative role of adipose tissue in growth and metabolism of colon cancer cells. Front Oncol 2014; 4:164.
151. Pérez-Hernández AI, Catalán V, Gómez-Ambrosi J, et al. Mechanisms linking excess adiposity and carcinogenesis promotion. Front Endocrinol (Lausanne) 2014; 5:65.
152. Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: E745-751.
153. Kim JH, Bachmann RA, Chen J. Interleukin-6 and insulin resistance. Vitamins & Hormones 2009; 80: 613-633.
154. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-a and IL-6. Diabetes Research and Clinical Practice 2005; 69(1): 29-35.
155. Syed V, Ulinski G, Mok SC, Ho SM. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. Journal of the National Cancer Institute 2002; 94(8): 617-629.
156. Sriuranpong V, Park JI, Amornphimoltham P, et al. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Research 2003; 63(11): 2948-2956.
157. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. American Journal of Pathology 2001; 159(6): 2159-2165.
158. Li YY, Hsieh LL, Tang RP, et al. Interleukin-6 (IL-6) released by macrophages induces IL-6 secretion in the human colon cancer HT-29 cell line. Human Immunology 2009; 70(3): 151-158.
159. Pei BX, Sun BS, Zhang ZF, et al. Interstitial tumor-associated macrophages combined with tumor-derived colony-stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non-small cell lung cancer. J Thorac Cardiovasc Surg 2014; 148(4): 1208-1216.e2.
160. Chen ZY, Raghav K, Lieu CH, et al. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer 2015; 112(6): 1088-1097.
161. Tripsianis G, Papadopoulou E, Anagnostopoulos K, et al. Coexpression of IL-6 and TNF-a: prognostic significance on breast cancer outcome. Neoplasma 2014; 61(2): 205-212.
162. Juretic M, Cerovic R, Belušic-Gobic M, et al. Salivary levels of TNF-a and IL-6 in patients with oral premalignant and malignant lesions. Folia Biol (Praha) 2013; 59(2): 99-102.
163. Wolf JS, Chen Z, Dong G, et al. IL (interleukin)-1 alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 2001; 7(6): 1812-1820.
164. Jung YJ, Isaacs JS, Lee S, et al. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003; 17(14): 2115-2117.
165. van de Woestijne AP, Monajemi H, Kalkhoven E, Visseren FL. Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management. Obes Rev 2011; 12(10): 829-840.
166. Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001; 60(3): 349-356.
167. Vergès B. Lipid modification in type 2 diabetes: the role of LDL and HDL. Fundam Clin Pharmacol 2009; 23(6): 681-685.
168. Soares FL, de Oliveira Matoso R, Teixeira LG, et al. Gluten-free diet reduces adiposity, inflammation and insulin resistance associated with the induction of PPAR-alpha and PPAR-gamma expression. J Nutr Biochem 2013; 24(6): 1105-1111.
169. Takahashi M, Hiyama Y, Yokoyama M, et al. In vivo arterial lipoprotein lipase expression augments inflammatory responses and impairs vascular dilatation. Arterioscler Thromb Vasc Biol 2008; 28(3): 455-462.
170. Wang L, Gill R, Pedersen TL, et al. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J Lipid Res 2009; 50(2): 204-213.
171. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002; 20: 42-51.
172. Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008; 9: 1039-1047.
173. Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008; 300: 2754-2764.
174. Wood IS, de Heredia FP, Wang B, Trayhurn P. Cellular hypoxia and adipose tissue dysfunction in obesity. Proc Nutr Soc 2009; 68(4): 370-377.
175. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005; 25(10): 2062-2068.
176. Kohlgruber A, Lynch L. Adipose Tissue Inflammation in the Pathogenesis of Type2 Diabetes. Curr Diab Rep 2015; 15(11): 92.
177. Subramanian M, Ozcan L, Ghorpade DS, et al. Suppression of Adaptive Immune Cell Activation Does Not Alter Innate Immune Adipose Inflammation or Insulin Resistance in Obesity. PLoS One 2015; 10(8):e0135842.
178. Zhao L, Fu Z, Wu J, et al. Inflammation-induced microvascular insulin resistance is an early event in diet-induced obesity. Clin Sci (Lond) 2015; 129(12): 1025-1036.
179. Pedersen DJ, Guilherme A, Danai LV et al. A major role of insulin in promoting obesity-associated adipose tissue inflammation. Mol Metab 2015; 4(7): 507-518.
180. Chen L, Chen R, Wang H, Liang F. Mechanisms Linking Inflammation to Insulin Resistance. Int J Endocrinol 2015; 2015:508409. doi: 10.1155/2015/508409.
181. Wieser V, Moschen AR, Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. Arch Immunol Ther Exp (Warsz) 2013; 61(2): 119-125.
182. Barbarroja N, Lopez-Pedrera C, Garrido-Sanchez L, et al. Progression from high insulin resistance to type 2 diabetes does not entail additional visceral adipose tissue inflammation. PLoS One 2012; 7(10): e48155.
183. Barbarroja N, López-Pedrera R, Mayas MD, et al. The obese healthy paradox: is inflammation the answer? Biochem J 2010; 430(1): 141-149.
184. Hu Y, Deng F, Song J, et al. Evaluation of miR-29c inhibits endotheliocyte migration and angiogenesis of human endothelial cells by suppressing the insulin like growth factor 1. Am J Transl Res 2015; 7(5): 866-877.
185. Brahmkhatri VP, Prasanna C, Atreya HS. Insulin-like growth factor system in cancer: novel targeted therapies. Biomed Res Int 2015; 2015:538019.
186. Liu Q, Xu Z, Mao S, et al. Effect of hypoxia on hypoxia inducible factor-1a, insulin-like growth factor I and vascular endothelial growth factor expression in hepatocellular carcinoma HepG2 cells. Oncol Lett 2015; 9(3): 1142-1148.
187. Ma W, Zhang T, Pan J, et al. Assessment of insulin-like growth factor 1 receptor as an oncogene in esophageal squamous cell carcinoma and its potential implication in chemotherapy. Oncol Rep 2014; 32(4): 1601-1609.
188. Wood IS, de Heredia FP, Wang B, Trayhurn P. Cellular hypoxia and adipose tissue dysfunction in obesity. Proc Nutr Soc 2009; 68(4): 370-377.
189. Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br J Nutr 2008; 100(2): 227-235.
190. Kang YS. Obesity associated hypertension: new insights into mechanism. Electrolyte Blood Press 2013; 11(2): 46-52.
191. Lafontan M. Adipose tissue and adipocyte dysregulation. Diabetes Metab 2014; 40(1): 16-28.
192. Algire C, Medrikova D, Herzig S. White and brown adipose stem cells: from signaling to clinical implications. Biochim Biophys Acta 2013; 1831(5): 896-904.
193. Murdolo G, Piroddi M, Luchetti F, et al. Oxidative stress and lipid peroxidation by-products at the crossroad between adipose organ dysregulation and obesity-linked insulin resistance. Biochimie 2013; 95(3): 585-594.
194. Sansbury BE, Cummins TD, Tang Y, et al. Overexpression of endothelial nitric oxide synthase prevents diet-induced obesity and regulates adipocyte phenotype. Circ Res 2012; 111(9): 1176-1189.
195. Fredriksson JM, Nikami H, Nedergaard J. Cold-induced expression of the VEGF gene in brown adipose tissue is independent of thermogenic oxygen consumption. FEBS Lett 2005; 579(25): 5680-5684
196. Shimizu I, Aprahamian T, Kikuchi R, et al. Vascular rarefaction mediates whitening of brown fat in obesity. J Clin Invest 2014; 124(5): 2099-2112.
197. Bhattacharya I, Domínguez AP, Drägert K, et al. Hypoxia potentiates tumor necrosis factor-a induced expression of inducible nitric oxide synthase and cyclooxygenase-2 in white and brown adipocytes. Biochem Biophys Res Commun. 2015 May 29;461(2):287-92.
198. Vernochet C, Damilano F, Mourier A, et al. Adipose tissue mitochondrial dysfunction triggers a lipodystrophic syndrome with insulin resistance, hepatosteatosis, and cardiovascular complications. FASEB J 2014; 28(10): 4408-4419.
199. Trayhurn P, Alomar SY. Oxygen deprivation and the cellular response to hypoxia in adipocytes -perspectives on white and brown adipose tissues in obesity. Front Endocrinol (Lausanne) 2015; 6:19. doi: 10.3389/fendo.2015.00019. eCollection 2015.
200. Trayhurn P. Hypoxia and adipocyte physiology: implications for adipose tissue dysfunction in obesity. Annu Rev Nutr 2014; 34: 207-236.
201. Netzer N, Gatterer H, Faulhaber M, et al. Hypoxia, Oxidative Stress and Fat. Biomolecules 2015; 5(2): 1143-1150.
202. Closa D, Folch-Puy E. Oxygen free radicals and the systemic inflammatory response. IUBMB Life 2004; 56(4): 185-191.
203. Belarbi Y, Mejhert N, Lorente-Cebrián S, et al. MicroRNA-193b Controls Adiponectin Production in Human White Adipose Tissue. J Clin Endocrinol Metab 2015; 100(8): E1084-1088.
204. Omatsu-Kanbe M, Matsuura H. Novel intracellular mediator of adiponectin secretion from adipocytes. J Physiol 2014; 592(Pt 23): 5141.
205. Cao Y. Angiogenesis and vascular functions in modulation of obesity, adipose metabolism, and insulin sensitivity. Cell Metab 2013; 18(4): 478-489.
206. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis 2000; 21(3): 361-370.
207. Klaunig JE, Kamendulis LM, Hocevar BA. Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol 2010; 38(1): 96-109.
208. Hwang ES, Bowen PE. DNA damage, a biomarker of carcinogenesis: its measurement and modulation by diet and environment. Crit Rev Food Sci Nutr 2007; 47(1): 27-50.
209. Sears B, Perry M. The role of fatty acids in insulin resistance. Lipids Health Dis 2015; 14(1): 121. doi: 10.1186/s12944-015-0123-1
210. Derosa G, Fogari E, D'Angelo A, et al. Adipocytokine levels in obese and non-obese subjects: an observational study. Inflammation 2013; 36(4): 914-920.
211. Matafome P, Santos-Silva D, Sena CM, Seiça R. Common mechanisms of dysfunctional adipose tissue and obesity-related cancers. Diabetes Metab Res Rev 2013; 29(4): 285-295.
212. Sethi JK, Vidal-Piug AJ. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res 2007; 48: 1253-1262.
213. Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev 1998; 78: 783-809.
214. Ruan H, Zarnowski MJ, Cushman SW, Lodish HF. Standard isolation of primary adipose cells from mouse epididymal fat pads induces inflammatory mediators and down-regulates adipocyte genes. J Biol Chem 2003; 278 (48): 47585-47593.
215. Schwartz B, Yehuda-Shnaidman E. Putative role of adipose tissue in growth and metabolism of colon cancer cells. Front Oncol 2014; 4: 164.
216. Nieman KM, Kenny HA, Penicka CV, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011; 17(11): 1498-1503.
217. Zhang Y, Nowicka A, Solley TN, et al. Stromal Cells Derived from Visceral and Obese Adipose Tissue Promote Growth of Ovarian Cancers. PLoS One 2015; 10(8): e0136361.
218. Jung YY, Lee YK, Koo JS. Expression of cancer-associated fibroblast-related proteins in adipose stroma of breast cancer. Tumour Biol 2015; 36(11): 8685-95.
219. Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Investig 2015; 21(1): 57-74.
220. Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumor genesis by enhancing IL-6 and TNF expression. Cell 2010; 140(2): 197-208.